Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $51.22.
A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th. Robert W. Baird lifted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research report on Thursday, October 17th. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Finally, Barclays cut their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 5th.
View Our Latest Analysis on Twist Bioscience
In related news, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $64,580.80. Following the completion of the sale, the chief accounting officer now owns 45,620 shares in the company, valued at approximately $2,034,652. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dennis Cho sold 1,507 shares of the business's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the completion of the transaction, the insider now directly owns 91,163 shares of the company's stock, valued at $4,375,824. The trade was a 1.63 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. Signaturefd LLC boosted its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience during the 2nd quarter worth $43,000. Blue Trust Inc. boosted its holdings in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the second quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after purchasing an additional 381 shares during the last quarter.
NASDAQ:TWST opened at $41.43 on Tuesday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -10.85 and a beta of 1.78. Twist Bioscience has a 1-year low of $23.00 and a 1-year high of $60.90. The firm's fifty day moving average price is $43.98 and its 200 day moving average price is $46.18.
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.